» Articles » PMID: 32131897

Levofloxacin-ceftazidime Administration Regimens Combat Pseudomonas Aeruginosa in the Hollow-fiber Infection Model Simulating Abnormal Renal Function in Critically Ill Patients

Overview
Publisher Biomed Central
Specialty Pharmacology
Date 2020 Mar 6
PMID 32131897
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of this study was to investigate the bactericidal effects of levofloxacin and ceftazidime as both monotherapy and combination therapy, and to determine their effects on resistance suppression in patients with normal and abnormal (Ccr:16-20 mL/min) renal function. Common clinical administration regimens to provide reference values were further evaluated.

Methods: The 7-d hollow-fiber infection model was used to inject the Pseudomonas aeruginosa standard strain (ATCC27853), which simulated common clinical administration regimens for patients with different renal function. Ten regimens were stratified into 2 categories based on renal function, and each category contained 3 monotherapy regimens and 2 combination therapy regimens. Total and resistant populations were quantified. Drug concentrations were determined by high-performance liquid chromatography (HPLC).

Results: Monotherapy regimens resulted in about 0.5-log-CFU/mL bacterial kill in the total population at 6 or 8 h, whilst combination regimens resulted in 2- to 3-log-CFU/mL within 2 days. For levofloxacin monotherapy regimens in patients with normal renal function, resistance emergence was seen after 6 h, and was seen at 0 h in the ceftazidime monotherapy regimen, as well as in all regimens of patients with abnormal renal function. Although resistant subpopulation in combination regimens with abnormal renal function began to increase at 0 h, there was a definite downward trend after 8 h, while resistant population in the normal renal function group increased after 16 h.

Conclusions: Combination therapy had greater bactericidal efficacy and resistance inhibition compared with monotherapy. Studying combination regimens in randomized clinical trials is warranted.

Citing Articles

Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?.

Vasikasin V, Rawson T, Holmes A, Otter J JAC Antimicrob Resist. 2023; 5(2):dlad036.

PMID: 37008824 PMC: 10050941. DOI: 10.1093/jacamr/dlad036.


The Application of Hollow Fiber Cartridge in Biomedicine.

Hou Y, Mi K, Sun L, Zhou K, Wang L, Zhang L Pharmaceutics. 2022; 14(7).

PMID: 35890380 PMC: 9316653. DOI: 10.3390/pharmaceutics14071485.


Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant in a Hollow Fiber Infection Model.

Wang S, Liu H, Mao J, Peng Y, Yan Y, Li Y Front Microbiol. 2021; 12:779885.

PMID: 34970238 PMC: 8714187. DOI: 10.3389/fmicb.2021.779885.


Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model.

Eales B, Hudson C, Kesisoglou I, Wang W, Nikolaou M, Tam V Antibiotics (Basel). 2021; 10(10).

PMID: 34680836 PMC: 8532833. DOI: 10.3390/antibiotics10101256.


Clinical efficacy of ceftazidime combined with levofloxacin on heart failure complicated with pulmonary infection and its influence on cardiopulmonary function.

Yang R, Li Y, Li J, Xing L, Liu L Am J Transl Res. 2021; 13(4):2590-2598.

PMID: 34017418 PMC: 8129224.

References
1.
Zhao X, Drlica K . Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001; 33 Suppl 3:S147-56. DOI: 10.1086/321841. View

2.
Crandon J, Schuck V, Banevicius M, Beaudoin M, Nichols W, Tanudra M . Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012; 56(12):6137-46. PMC: 3497209. DOI: 10.1128/AAC.00851-12. View

3.
Fink M, Snydman D, Niederman M, Leeper Jr K, Johnson R, Heard S . Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994; 38(3):547-57. PMC: 284496. DOI: 10.1128/AAC.38.3.547. View

4.
Jumbe N, Louie A, Leary R, Liu W, Deziel M, Tam V . Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003; 112(2):275-85. PMC: 164285. DOI: 10.1172/JCI16814. View

5.
Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G . Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2017; 32(4):e22339. PMC: 6817019. DOI: 10.1002/jcla.22339. View